Alemtuzumab in Stem Cell Transplantation
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in Medical Oncology
- Vol. 19 (2S) , S33-S48
- https://doi.org/10.1385/mo:19:2s:s33
Abstract
Alemtuzumab, otherwise called CAMPATH-1H, is a humanized monoclonal antibody directed against the CD52 antigen of lymphocytes. It is one of a family of CAMPATH-1 antibodies that have been used over...Keywords
This publication has 63 references indexed in Scilit:
- High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitutionBlood, 2002
- Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitutionBlood, 2002
- Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimenBlood, 2002
- The CD52 antigen and development of the CAMPATH antibodiesCytotherapy, 2001
- Immune reconstitution following hematopoietic stem-cell transplantationCytotherapy, 2001
- Finally! the Brambell receptor (FcRB)Immunologic Research, 1997
- Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors.1996
- Effect of Campath-1H antibody on human hematopoietic progenitors in vitro.1993
- BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH CHRONIC MYELOID-LEUKEMIA - T-CELL DEPLETION WITH CAMPATH-1 REDUCES THE INCIDENCE OF GRAFT-VERSUS-HOST DISEASE BUT MAY INCREASE THE RISK OF LEUKEMIC RELAPSE1986
- Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans.1983